Victor Sandor - 01 Jul 2026 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Reporting relationship: Director
Issuer ticker: ABCL
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 18:04:55 UTC
Prior SEC filing: 25 Jun 2026
Source filing: View source filing
Reporting owner signature: Tryn Stimart, attorney-in-fact

Key filing fact

Victor Sandor filed Form 4 for AbCellera Biologics Inc. (ABCL) on 06 Jul 2026.

Key facts

This page summarizes Victor Sandor's Form 4 filing for AbCellera Biologics Inc. (ABCL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 18:04.

Change

Previous filing in this sequence was filed on 25 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001620368 Primary reporting owner

Sandor Victor

Relationship: Director
Address: C/O ABCELLERA BIOLOGICS INC, 150 W 4TH AVENUE, VANCOUVER, BRITISH COLUMBIA, CANADA
Signature: Tryn Stimart, attorney-in-fact
Signature date: 06 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABCL transaction Derivative

Share option (right to buy)

Award

Transaction value
Shares: +152,207
Change %
Price: $0.000000^*
Shares after: 152,207
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 152,207
Exercise price: $7.85
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.